Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APTO NASDAQ:CGEN NASDAQ:MGTX NASDAQ:PRTO NASDAQ:VCEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPTOAptose Biosciences$4.41$1.35▼$50.10$3.66M1.04227,964 shs650,294 shsCGENCompugen$2.24+21.1%$1.50$1.13▼$2.66$165.09M2.61405,707 shs1.55 million shsMGTXMeiraGTx$7.83-0.1%$7.86$4.23▼$8.98$630.71M1.34396,846 shs330,798 shsPRTOProteon Therapeutics$5.34+2.3%$19.37$0.22▼$3.94$118.44M0.61.11 million shs537,137 shsVCELVericel$33.49+5.1%$33.84$29.24▼$63.00$1.61B1.39809,486 shs657,466 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPTOAptose Biosciences0.00%0.00%0.00%0.00%-84.43%CGENCompugen+21.08%+25.14%+67.16%+41.77%+30.23%MGTXMeiraGTx-0.13%-6.90%+2.89%-8.63%+84.24%PRTOProteon Therapeutics0.00%+5.24%+66.24%+65.19%+210.71%VCELVericel+5.15%-0.74%+4.07%-9.73%-19.67%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPTOAptose Biosciences$4.41$1.35▼$50.10$3.66M1.04227,964 shs650,294 shsCGENCompugen$2.24+21.1%$1.50$1.13▼$2.66$165.09M2.61405,707 shs1.55 million shsMGTXMeiraGTx$7.83-0.1%$7.86$4.23▼$8.98$630.71M1.34396,846 shs330,798 shsPRTOProteon Therapeutics$5.34+2.3%$19.37$0.22▼$3.94$118.44M0.61.11 million shs537,137 shsVCELVericel$33.49+5.1%$33.84$29.24▼$63.00$1.61B1.39809,486 shs657,466 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPTOAptose Biosciences0.00%0.00%0.00%0.00%-84.43%CGENCompugen+21.08%+25.14%+67.16%+41.77%+30.23%MGTXMeiraGTx-0.13%-6.90%+2.89%-8.63%+84.24%PRTOProteon Therapeutics0.00%+5.24%+66.24%+65.19%+210.71%VCELVericel+5.15%-0.74%+4.07%-9.73%-19.67%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPTOAptose Biosciences 3.50Strong Buy$6.00∞ UpsideCGENCompugen 2.00Hold$4.0078.57% UpsideMGTXMeiraGTx 2.33Hold$24.00206.51% UpsidePRTOProteon Therapeutics 0.00N/AN/AN/AVCELVericel 2.50Moderate Buy$60.4080.35% UpsideCurrent Analyst Ratings BreakdownLatest APTO, MGTX, PRTO, VCEL, and CGEN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025CGENCompugenWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025MGTXMeiraGTxWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025VCELVericelWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)9/27/2025CGENCompugenWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025MGTXMeiraGTxWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025VCELVericelWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)9/17/2025VCELVericelBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral8/15/2025MGTXMeiraGTxChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$35.008/1/2025VCELVericelCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$61.00 ➝ $58.00(Data available from 10/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPTOAptose BiosciencesN/AN/AN/AN/A($0.19) per shareN/ACGENCompugen$27.86M7.18N/AN/A$0.62 per share3.61MGTXMeiraGTx$33.28M18.93N/AN/A$0.87 per share9.00PRTOProteon TherapeuticsN/AN/AN/AN/A($0.06) per shareN/AVCELVericel$237.22M7.12$0.33 per share101.92$5.92 per share5.66Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPTOAptose Biosciences-$51.21M-$89.19N/AN/AN/AN/A-5,683.22%-300.44%N/ACGENCompugen-$14.23M-$0.22N/AN/AN/A-87.45%-34.77%-16.82%11/11/2025 (Estimated)MGTXMeiraGTx-$147.79M-$2.04N/A20.61N/A-415.39%-314.44%-63.28%11/12/2025 (Estimated)PRTOProteon Therapeutics-$20.73M-$1.15N/AN/AN/AN/AN/A-118.68%N/AVCELVericel$10.36M$0.12279.1176.11N/A2.85%2.47%1.69%11/6/2025 (Estimated)Latest APTO, MGTX, PRTO, VCEL, and CGEN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025CGENCompugen-$0.09N/AN/AN/A$1.47 millionN/A11/6/2025Q3 2025VCELVericel-$0.02N/AN/AN/A$64.57 millionN/A8/14/2025Q2 2025MGTXMeiraGTx-$0.52-$0.48+$0.04-$0.48$8.00 million$3.69 million8/6/2025Q2 2025CGENCompugen-$0.07-$0.08-$0.01-$0.08$3.95 million$1.26 million7/31/2025Q2 2025VCELVericel-$0.04-$0.01+$0.03-$0.01$64.61 million$63.24 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPTOAptose BiosciencesN/AN/AN/AN/AN/ACGENCompugenN/AN/AN/AN/AN/AMGTXMeiraGTxN/AN/AN/AN/AN/APRTOProteon TherapeuticsN/AN/AN/AN/AN/AVCELVericelN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPTOAptose BiosciencesN/A1.051.05CGENCompugenN/A4.744.74MGTXMeiraGTx26.290.880.88PRTOProteon TherapeuticsN/A5.985.98VCELVericelN/A4.974.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPTOAptose Biosciences26.62%CGENCompugen12.22%MGTXMeiraGTx67.48%PRTOProteon Therapeutics23.03%VCELVericelN/AInsider OwnershipCompanyInsider OwnershipAPTOAptose Biosciences1.33%CGENCompugen9.50%MGTXMeiraGTx7.50%PRTOProteon Therapeutics45.70%VCELVericel7.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPTOAptose Biosciences312.14 million63.45 millionNo DataCGENCompugen7089.24 million80.76 millionOptionableMGTXMeiraGTx30080.45 million74.41 millionOptionablePRTOProteon Therapeutics1722.18 millionN/ANot OptionableVCELVericel30050.46 million46.83 millionOptionableAPTO, MGTX, PRTO, VCEL, and CGEN HeadlinesRecent News About These CompaniesVericel Corporation (NASDAQ:VCEL) Receives Consensus Rating of "Moderate Buy" from AnalystsOctober 10, 2025 | marketbeat.comVericel (NASDAQ:VCEL) Receives "Sell (D+)" Rating from Weiss RatingsOctober 9, 2025 | marketbeat.comVericel Corporation $VCEL Shares Purchased by PFG Investments LLCOctober 4, 2025 | marketbeat.comCanaccord Genuity Keeps Their Buy Rating on Vericel (VCEL)September 26, 2025 | theglobeandmail.comVericel Corporation $VCEL Shares Acquired by Congress Asset Management Co.September 26, 2025 | marketbeat.comVericel (NASDAQ:VCEL) Hits New 12-Month Low - Time to Sell?September 25, 2025 | marketbeat.comKopp Family Office LLC Sells 8,554 Shares of Vericel Corporation $VCELSeptember 24, 2025 | marketbeat.comVoya Investment Management LLC Purchases 10,048 Shares of Vericel Corporation $VCELSeptember 24, 2025 | marketbeat.com18,200 Shares in Vericel Corporation $VCEL Purchased by Strs OhioSeptember 20, 2025 | marketbeat.comDeclining Stock and Decent Financials: Is The Market Wrong About Vericel Corporation (NASDAQ:VCEL)?September 18, 2025 | finance.yahoo.comVericel (NASDAQ:VCEL) Shares Gap Down After Analyst DowngradeSeptember 18, 2025 | marketbeat.comVericel (NASDAQ:VCEL) Downgraded to Neutral Rating by BTIG ResearchSeptember 18, 2025 | marketbeat.comVericel (NASDAQ:VCEL) Reaches New 52-Week Low on Analyst DowngradeSeptember 18, 2025 | marketbeat.comVericel downgraded to Neutral from Buy at BTIGSeptember 17, 2025 | msn.comBTIG Downgrades Vericel (VCEL)September 17, 2025 | msn.comIntech Investment Management LLC Buys 18,274 Shares of Vericel Corporation $VCELSeptember 17, 2025 | marketbeat.comVericel Corporation (NASDAQ:VCEL) Given Average Recommendation of "Buy" by BrokeragesSeptember 16, 2025 | marketbeat.comHere’s Why Vericel Corp. (VCEL) Traded Down in Q2September 12, 2025 | msn.comIs the Options Market Predicting a Spike in Vericel Stock?September 11, 2025 | zacks.comVericel’s Phase 3 Study on MACI: A Potential Game-Changer in Cartilage RepairSeptember 7, 2025 | tipranks.comVericel to Present at the Wells Fargo Healthcare Conference on Thursday, September 4, 2025August 28, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAPTO, MGTX, PRTO, VCEL, and CGEN Company DescriptionsAptose Biosciences NASDAQ:APTOAptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.Compugen NASDAQ:CGEN$2.24 +0.39 (+21.08%) Closing price 10/13/2025 04:00 PM EasternExtended Trading$2.26 +0.02 (+0.89%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.MeiraGTx NASDAQ:MGTX$7.83 -0.01 (-0.13%) Closing price 10/13/2025 04:00 PM EasternExtended Trading$7.84 +0.00 (+0.06%) As of 04:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.Proteon Therapeutics NASDAQ:PRTOProteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. Its lead product candidate is vonapanitase, an investigational drug intended to enhance hemodialysis vascular access outcomes. The company develops vonapanitase, a recombinant human elastase, which has completed Phase II and Phase III clinical trials for patients with chronic kidney disease. It is also evaluating vonapanitase in a Phase I clinical trial in patients with peripheral artery disease. The company was founded in 2001 and is based in Waltham, Massachusetts.Vericel NASDAQ:VCEL$33.49 +1.64 (+5.15%) Closing price 10/13/2025 04:00 PM EasternExtended Trading$33.32 -0.17 (-0.50%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise D-Wave: Reevaluating the Short Seller’s Case After the Downgrade 2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk Applied Digital’s Shorts Got Squeezed—Now What? Levi Strauss Stock Set to Reach New Highs in 2026 Alphabet: The AI Powerhouse Driving Markets Into 2026 Is the Reddit-ChatGPT Love Affair Over? Broadcom Gets Second $420 Target as CPO Win Boosts Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
